Pharmacuetical
-
US General Medicines restructuring results in reduction of 1,960 positions
-
Action reflects impending loss of Diovan patent exclusivity in US and expected impact on worldwide sales of Rasilez/Tekturna after ALTITUDE study termination
-
US restructuring to lead to an exceptional charge of USD 160 million in the first quarter of 2012 and to annual savings of approximately USD 450 million by 2013
-
Reassessment of future sales potential of Rasilez/Tekturna leads to an exceptional charge of approximately USD 900 million in fourth quarter 2011
-
In addition, as part of ongoing portfolio review, Novartis to take an exceptional charge of approximately USD 160 million related to termination of PRT128 (elinogrel) and SMC021(oral calcitonin) programs
rest of press release at : http://www.novartis.com/newsroom/
The Los Angeles Times reports Amgen is laying off about 380 employees in its research and development division, 226 employees in Thousand Oaks, California.
The Philadelphia Inquirer reports that AstraZeneca 400 pharmaceutical industry jobs, primarily at it’s US headquarters in Wilmington Delaware.
http://www.daytondailynews.com/ reports Humana will expand it’s RightSource mail order pharmacy business and add 200 jobs in the greater Cincinatti Ohio area.
The newsobserver.com website reports that Merck will add 150 jobs to a facility in Durham NC.
The Merck plant makes vaccines, including the chickenpox vaccine.
Boston.com reports that the Pharmaceutical company Pfizer will add about 450 jobs in the Boston area, even as it eliminates 1,100 jobs in Groton, Conn., about a quarter of its workforce there.